The Natural History of Hormone Receptor–Positive Breast Cancer

摘要: Abstract: Approximately 70% of human breast tumors express hormone receptors (HRs), comprising the estrogen receptor (ER) and/or progesterone (PR).The ER is primary transcription factor driving oncogenesis in HR-positive (HR+) cancers; it both a target of, and predictor response to, antiestrogen therapy. Unlike other cancer subtypes, more than half all disease recurrences HR+ occur 6 years or after diagnosis, particularly following 5 adjuvant anti-estrogen Late relapses thus represent significant clinical challenge. There considerable molecular heterogeneity underlying cancers, limited understanding mechanisms treatment resistance late relapse. In this review, we describe long natural history discuss relapse patterns relation to their clinicopathological characteristics. We highlight relationship between tumor therapy resistance, concept dormancy. Finally, review novel translational research strategies utilizing preclinical models patient samples, current that address increasingly common challenge cancer.